Approved by the EMA and FDA in 2019, oral formulations of Tafamidis are employed in the treatment of transthyretin (TTR) amyloidosis in adult patients with early-stage symptomatic polyneuropathy to delay peripheral neurological impairment of TTR familial amyloid polyneuropathy. Here, TTR is linked to familial amyloid neuropathy.